Dr. Erin Michos is an Associate Professor in the Division of Cardiology at the Johns Hopkins School of Medicine, with joint appointment in Epidemiology at the Johns Hopkins Bloomberg School of Public Health. She is the Associate Director of Preventive Cardiology Dr. Michos is an internationally known expert in Preventive Cardiology and Women’s Health, having authored 600 publications and 11 book chapters. Her research involves (1) Cardio-Obstetrics and women’s cardiovascular health; (2) coronary artery calcium, inflammation and other biomarkers; (3) lipids; and (4) diabetes & cardio-metabolic disease. She is the co-Editor-in-Chief for the American Journal of Preventive Cardiology, an Associate Editor for Circulation, a member of the Board of Directors for the American Society of Preventive Cardiology (ASPC), and a member of the American College of Cardiology (ACC) Prevention Leadership Council. She is also a member of ACC’s Clinical Quality Approval Committee (CPAC). Dr. Michos has also held several leadership positions within the American Heart Association (AHA) including being a member of the AHA Funding Committee. Dr. Michos is a co-investigator in several NIH-funded studies including the Multi-Ethnic Study of Atherosclerosis (MESA) and the Atherosclerosis Risk in Communities (ARIC) cohorts. She is the Training Director for three AHA Strategic Focused Research Networks. She has mentored over 60 individuals in her career and was the recipient of 2 mentoring awards at Johns Hopkins University. Dr. Michos completed medical school at Northwestern University, Internal Medicine residency and Cardiology fellowship at Johns Hopkins Hospital, and a Masters of Health Science degree at Johns Hopkins School of Public Health.
General Statement of Disclosure:
CONSULTING FEES/HONORARIA: Novartis Corporation(MODEST), AstraZeneca Pharmaceuticals(MODEST), Bayer Healthcare Pharmaceuticals(MODEST), Pfizer Inc(MODEST), Novo Nordisk Inc.(SIGNIFICANT), Edwards Lifesciences(MODEST), Medtronic(MODEST), Boehringer Ingelheim Pharmaceuticals, Inc(SIGNIFICANT), Amgen Inc.(MODEST), Amarin(MODEST), Esperion(SIGNIFICANT)